DigestRedComo funciona
Red
/
Empresas
Re
No verificado

RevBio, Inc.

Sobre qué escribimos

BiotecnologíaHigiene alimentariaIndustriaMedicina alternativaMultimedia

10 Comunicados de prensa

Ver todos los comunicados de prensa
02/09/2026
REVBIO Publishes in NPJ Microgravity the Results of its TETRANITE® Bone Regeneration Study Conducted Onboard the International Space Station
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
28/01/2026
FDA Greenlights RevBio’s Pivotal Clinical Trial for its Cranial Flap Bone Glue
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
22/12/2025
RevBio® Receives Approval from FDA to Start a Dental Clinical Trial for its Regenerative Bone Glue
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
04/11/2025
RevBio® Receives First FDA Approval for a "Bone Glue" to Treat Extremity Fractures in a Clinical Trial
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
06/10/2025
RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
29/05/2025
RevBio Expands Globally into the United Kingdom with its Second Cranial Flap Fixation Clinical Trial for its Regenerative Bone Adhesive
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
17/03/2025
Multimedia
Industria
Ciencia
Material médico sanitario
Medicina - Varios
Higiene alimentaria
Odontología
Biotecnología
Medicina alternativa
Salud
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
30/01/2025
RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
11/12/2024
Multimedia
Industria
Sanidad
Ciencia
Material médico sanitario
Medicina - Varios
Biotecnología
Medicina alternativa
Higiene alimentaria
Salud
RevBio Receives Both FDA Approval to Expand its Clinical Trial and CMS Reimbursement for its Regenerative Bone Adhesive for Cranial Flap Fixation
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0
16/09/2024
RevBio Receives a $2.4 Million NIH Grant to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation and Enrolls First Five Patients
Fuente
RevBio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0